Clinical Trial Update: Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cediranib in patients with recurrent or metastatic renal cell carcinoma not removable by surgery; study completed and results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-29